Lynk Pharmaceuticals Announces NMPA Acceptance of New Drug Application for Zemprocitinib in the Treatment of Rheumatoid Arthritis
SHANGHAI and HANGZHOU, China and BOSTON, Nov. 5, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced...













